NCT02677155View on ClinicalTrials.gov

Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Follicular Lymphoma
Interventions
RADIATION

Radiotherapy

Radiotherapy 8 Gy single dose

BIOLOGICAL

Rituximab

Intranodal injection 5 mg

BIOLOGICAL

Autologous dendritic cells

Intranodal injection of 1 x 10 e8 cells

BIOLOGICAL

GM-CSF

Subcutaneous injection of 50 ug

BIOLOGICAL

Pembrolizumab

Intravenous infusion of 200 mg

Trial Locations (1)

0310

Oslo University Hospital Radiumhospitalet, Oslo

All Listed Sponsors
collaborator

Norwegian Cancer Society

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Oslo University Hospital

OTHER

NCT02677155 - Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | Biotech Hunter | Biotech Hunter